Richardson , Alan - Keele University

个人简介

I joined the School of Pharmacy in 2008. Following a PhD and post-doctoral work in pharmacology at Cambridge, I completed my post-doctoral training at the University of Virginia, USA. Following several years leading drug discovery programs in industry (Johnson & Johnson, Belgium and OSI pharmaceuticals, Oxford) I returned to academic research at the Institute of Cancer Research in London. At Keele, I lead teaching of pharmacology including option topics focusing on oncology molecular therapeutics. I also make teaching contributions to the School of Life Sciences and the School of Medicine.

研究领域

My research interests focus on discovering new therapeutic targets and drugs for the treatment of ovarian cancer

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis ADM, Richardson A. 2013. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol, vol. 129(2), 417-424. link> doi> Stamelos VA, Robinson E, Redman CW, Richardson A. 2013. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. Gynecol Oncol, vol. 128(2), 377-382. link> doi> Richardson A, Underwood JK, Allin SM, Redman CW. 2012. Autotaxin - a target for the treatment of drug-resistant ovarian cancer?. In Ovarian cancer - basic science perspective. Farghaly S (Ed.). (vol. 1). Intech. link> Stamelos VA, Redman CW, Richardson A. 2012. Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal, vol. 7(1), 12. link> doi> Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A. 2010. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. CELLULAR SIGNALLING, vol. 22(6), 926-935. link> doi>